Highlights Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
6.46 ^USD	+2.87%		+2.05%	+50.93%

May. 09	Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration	May. 06	MT
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications	May. 06	CI
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion	Apr. 22	MT
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan	Apr. 22	CI
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284	Mar. 15	CI
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR	Mar. 04	CI
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers	Feb. 15	CI
Lantern Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma	23-10-03	CI
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors	23-09-25	CI
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin?s Lymphomas	23-09-18	CI
Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting	23-08-31	CI
Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors	23-08-28	CI
Lantern Pharma Receives US Patent Allowance Notice for LP-184 to Treat Rare Pediatric Brain Cancer	23-08-14	MT
Lantern Pharma Inc. Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT	23-08-14	CI
Lantern Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Oncotarget Publishes New Data by Lantern Pharma Further Supporting Clinical Advancement of LP-284, A Novel Synthetic Lethal Drug Candidate for Non-Hodgkin's Lymphomas	23-06-26	CI
Lantern Pharma Gets US FDA Clearance of Investigational New Drug Application for LP-184	23-06-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Highlights

Filters